**SOMATOSTATINOMA**

**Wouter W. de Herder, MD, PhD,** Professor of Endocrine Oncology, Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center and Erasmus MC Cancer Institute, Rotterdam, the Netherlands. w.w.deherder@erasmusmc.nl

**Wouter T. Zandee, MD, PhD,** Endocrinologist, Department of Internal Medicine, Division of Endocrinology, University Medical Center Groningen (UMCG), Groningen, the Netherlands

**Johannes Hofland, MD, PhD,** Endocrinologist, Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, and Erasmus MC Cancer Institute Rotterdam, the Netherlands

**Updated January 17, 2021**

**ABSTRACT**

Somatostatin-secreting tumors or somatostatinomas represent about 4% of gastrointestinal neuroendocrine neoplasms and their estimated incidence is about 1 in 40 million individuals per year. The spectrum of the somatostatinoma syndrome consists of diabetes mellitus, diarrhea/steatorrhea, cholelithiasis, hypochlorhydria, and weight loss. Hereditary pancreatic somatostatinomas can be found as part of multiple neuroendocrine neoplasia type 1 (MEN1) and von-Hippel Lindau (VHL) syndrome, whereas duodenal (peri-ampullary somatostatinomas can be found in patients with neurofibromatosis type 1 (NF1). The polycythemia-paraganglioma-somatostatinoma syndrome is a rare syndrome including multiple paragangliomas, duodenal somatostatinomas (exclusively found at the ampulla of Vater) associated with high erythropoietin (polycythemia) underlying paraganglioma/pheochromocytoma. The diagnosis of a somatostatinoma requires measuring fasting plasma somatostatin hormone concentration. A 3-phase CT, MRI, positron emission tomography (PET)-CT with gallium-labelled somatostatin analogs, or endoscopic ultrasonography should be performed for the precise localization of somatostatinomas in the pancreas or duodenum. A biopsy or surgical resection is required for grading (Ki67 index) and immunohistochemistry for somatostatin expression on tumor samples. Management of somatostatinomas includes medical treatment of the excess somatostatin production, surgical and/or radiological interventions, peptide receptor radiotherapy, and targeted or cytotoxic therapies.

**INTRODUCTION**

The tetradecapeptide somatostatin is the main peptide released from somatostatinomas. This hormone was successfully isolated in 1973 by Paul Brazeau and colleagues in the research group of the French-US endocrinologist and Nobel prize laureate Roger Guillemin (1). Somatostatin inhibits numerous endocrine and exocrine secretory functions. Almost all gut hormones are inhibited by somatostatin, including insulin, glucagon, gastrin, secretin, and gastric inhibitory polypeptide (GIP). In addition to inhibition of the endocrine secretions, somatostatin has direct effects on a number of other target organs. For example, it is an inhibitor of gastric acid and pancreatic enzyme secretion, it has marked effects on gastrointestinal transit time, intestinal motility, and absorption of nutrients from the small intestine. In the nervous system, somatostatin acts as a neurotransmitter or neuromodulator and its roles in the fine-tuning of neuronal activity and involvement in synaptic plasticity and memory formation are now widely recognized (2).

In 1977, the groups of the Danish physician Lars-Inge Larsson and that of the US physician Om P. Ganda independently reported the first two cases of pancreatic somatostatinoma (3, 4). In 1979, a full description of the somatostatinoma syndrome caused by a periampullary neuroendocrine tumor was reported by the Austrian gastroenterologist Günter Krejs and colleagues (5, 6). Since then, numerous cases have been reported, most of them being sporadic, but some of them now being recognized as part of classic or emerging genetic syndromes.

Somatostatinomas are very rare neuroendocrine neoplasms (NENs), representing about 4% of gastrointestinal NENs. Their estimated incidence is about 1 in 40 million individuals per year in the general population (7, 8).

**CLINICAL PRESENTATION**

Although somatostatinomas secrete somatostatin, clinical presentations related to high somatostatin levels are found in less than 5% of cases. This may depend on the location of the NEN (generally pancreatic), as well as intermittent somatostatin secretion from the NEN (3)(7). The spectrum of the somatostatinoma syndrome consists of diabetes mellitus, diarrhea/steatorrhea, cholelithiasis, hypochlorhydria, and weight loss. The majority of somatostatinomas do not present with the typical somatostatinoma symptoms, but are silent. The diagnosis in those cases is mainly based on the positive immunohistochemistry for somatostatin on tumor samples. Most NEN experts, however, consider these tumors not as silent somatostatinomas, but, if hypersecretion of other hormones is also absent, as clinically non-functioning NENs. These patients experience symptoms related to the tumor mass effect, their metastases, or the invasion of contiguous structures. Therefore, these silent NENs are generally detected by Computed Tomography (CT), Magnetic Resonance Imaging (MRI) or, on occasion, by Somatostatin Receptor Imaging (SRI) and Endoscopic Ultrasonography (EUS). The most common symptom for all somatostatinomas is abdominal pain, occurring in over 50% of patients. Duodenal tumors can also present with jaundice and gastrointestinal bleeding (7, 9, 10).

Secretion of different hormones by the same panNEN, sometimes resulting in two, or more synchronous, or metachronous distinct endocrine syndromes, is now being recognized with increasing frequency. However, second, or metachronous somatostatin secretion has thus far not been recognized. These possibilities should be considered during endocrine work-up and follow-up of patients with panNENs (11, 12).

Somatostatin has been found in many tissues outside the GI tract. Prominent among those are the hypothalamic and extrahypothalamic regions of the brain, the peripheral nervous system (including the sympathetic adrenergic ganglia), and the C cells of the thyroid gland. Therefore, high plasma concentrations of somatostatin have been found in tumors originating from these tissues (13). Pheochromocytomas and paragangliomas are other examples of neuroendocrine tumors (NETs) that produce and secrete somatostatin in addition to other hormonally active substances (14). However, these tumors do not present with signs or symptoms of the somatostatinoma syndrome.

**HEREDITARY TUMORS**


Hereditary pancreatic somatostatinomas can be found as part of multiple neuroendocrine neoplasia type 1 (MEN1) and von-Hippel Lindau (VHL) syndrome, whereas duodenal (peri-ampullary) somatostatinomas can be found in patients with neurofibromatosis type 1 (NF1) (15-19). An overview of the MEN1 syndrome is provided in the chapter on “MEN1”. Previously known as Von Recklinghausen disease, NF1, the most frequent neuro-cutaneous syndrome, is an autosomal dominant condition. The reported incidence is 1/2500-1/3000 (39,40). The mutation causing the condition is at the level of NF1 gene (on chromosome 17) which induces a malfunction of the RAS/MAPK pathway. The presence of a duodenal somatostatinoma has a higher risk in NF1 patients than in the general population, but this is not the most prevalent tumor encountered in these patients. Some studies report on the combined diagnosis of GIST and somatostatinoma in subjects with neurofibromatosis type 1 (7, 9, 10, 20-24).

The polycythemia-paraganglioma-somatostatinoma syndrome (also called Pacak-Zhuang syndrome) is a rare new syndrome including multiple paragangliomas, duodenal somatostatinomas (exclusively found in the region of the ampulla of Vater) and a high circulating erythropoietin concentration resulting in polycythemia. A gain of function involving the mutation of Endothelial PAS domain-containing protein 1 (EPAS1, also known as hypoxia-inducible factor-2alpha (HIF-2alpha)) gene underlies the Pacak-Zhuang syndrome. Moreover, non-mosaicism somatic mutations of HIF-2alpha seem to induce the same syndrome but with late onset. A somatic gain-of-function HIF-2alpha mutation results in the stabilization of HIF-2α, which is known to upregulate the erythropoietin gene accounting for polycythemia in these patients (24-32).

However, while the association of somatostatinomas with these inherited disorders is intriguing, a link between the known gene mutations of these disorders with the development of somatostatinomas has not been clearly established.

**DIAGNOSIS**

The diagnosis of somatostatinoma requires the combination of typical clinical signs and symptoms with measuring the fasting plasma somatostatin hormone concentration, which should be at least 3 times over the upper reference value. In case of an indeterminate test result, stimulatory examinations such as secretin or calcium stimulation tests can be used, but these tests lack standardization. Anatomic and functional imaging modalities are important in the localization of a somatostatinoma. As in other NENs, 3-phase CT, MRI, or EUS should be performed for the precise localization of these tumors in the pancreas or duodenum. To detect distant metastases, somatostatin receptor imaging should be used as somatostatinomas express high numbers of different somatostatin receptor subtypes. Currently, positron emission tomography (PET)-CT with gallium-labelled somatostatin analogs (DOTATATE, DOTANOC, DOTATOC) have the highest sensitivity for detecting metastases of grade 1-3 panNENs. In line with the work-up for all NENs, a biopsy is advised to confirm the diagnosis and for grading (Ki67 index), as the grade can influence treatment selection. An overview of the current staging and grading systems is provided in the chapter “Insulinoma”. Pathological examination and immunohistochemistry for somatostatin expression on tumor samples after surgery or biopsy confirms the definitive diagnosis (7, 33-37), see Figure 1.



**Figure 1. A malignant metastasizing pancreatic endocrine tumor 5cm in diameter located in the tail of the pancreas. Malignant non-syndromic pancreatic neuroendocrine tumor (G2) with immunohistochemical expression of somatostatin (Courtesy of Gunther Kloppel)**

**TREATMENT**

The management of somatostatinomas includes medical treatment of the excess somatostatin production, surgical and/or radiological interventions, and cytotoxic therapies when needed (35).

As for all panNENs, surgery is the only curative treatment. In the occasional patient in whom a somatostatinoma is discovered while the tumor is locoregionally confined, pancreatic or duodenal surgery should be performed to resect the somatostatinoma. In selected patients with limited liver metastases an extended surgical resection can be considered (38).

**Liver-Directed Therapy**

Liver metastases can be resected or treated by bland embolization, radioembolization (SIRT), radiofrequency ablation (RFA), microwave and cryoablation, high-intensity focused ultrasound (HIFU), laser, brachytherapy, and irreversible electroporation (IRE) depending on local availability (39-42).

In case of unresectable metastases, treatment is focused on tumor stabilization and symptom reduction by decreasing the secretion of somatostatin. In general, anti-tumor therapy is similar to non-functioning panNENs as specific data for somatostatinoma are often lacking. The guidelines by ENETS, NANETS and ESMO describe the selection and sequencing of somatostatin analogs, targeted therapy, 177Lu-DOTATATE, and cytotoxic chemotherapy (34, 43-45).

**Somatostatin Analogs**

Somatostatin analogs became an important treatment option for patients with metastatic or inoperable NENs. First, these analogs provide relief of symptoms in patients with NENs that secrete different peptides causing various clinical symptoms and signs, especially diarrhea and weight loss in somatostatinoma patients (46). Somatostatin analogs are the first-line palliative treatment of choice to control somatostatin secretion and tumor growth. In a randomized controlled trial (CLARINET), including grade 1-2 pancreatic NETs (panNETs), lanreotide autogel 120 mg every 4 weeks deep sc was associated with significantly prolonged median progression-free survival (PFS) of 38 months versus 18 months for placebo (47).

**Peptide Receptor Radionuclide Therapy**

The expression of somatostatin receptor subtypes provides an opportunity to utilize peptide receptor radionuclide therapy (PRRT) for the treatment of metastatic somatostatinomas. PRRT with 177Lu-DOTATATE has been approved for the treatment of grade 1-2 panNETs based on the NETTER-1 trial for midgut NET combined with prospective Erasmus MC, Rotterdam data for panNET. In general, the response rate for grade 1-2 panNETs is the highest of all NETs (55%), with a median PFS of 30 months and median overall survival (OS) of 71 months. Sub-acute toxicity mainly includes nausea, vomiting, and CTCAE grade 3/4 toxicity of hematologic parameters (10%). In 70% of patients with toxicity, the hematologic parameters normalize but 1% of patients treated with PRRT develops acute leukemia, and 2% myelodysplastic syndrome (48, 49). In patients with uncontrollable hypersecretion by hormone-producing panNENs, PRRT with 177Lu-DOTATATE can result in amelioration of the hormonal syndrome (50). However, data of PRRT with 177Lu-DOTATATE for the treatment of metastatic somatostatinoma are not available yet.

**Everolimus**

Everolimus is an oral drug which inhibits mammalian target of rapamycin (mTOR) signaling. In the RADIANT-3 trial, everolimus 10 mg/day increased progression-free survival in grade 1-2 panNETs to 11.0 months as compared to 4.6 months with placebo. Also, overall survival did increase from 37.6 to 44 months. In this study 24% of patients had a functioning grade 1-2 panNET including somatostatinomas (51, 52). As everolimus can also worsen diabetes mellitus by reducing insulin secretion from the pancreas and inducing insulin resistance, its contribution to the treatment of somatostatinoma patients is still unclear.

**Sunitinib**

Sunitinib is currently one of the other options for treatment of grade 1-2 panNETs which progress during treatment with a first generation long-acting somatostatin analog. In the SU011248 trial sunitinib 37.5 mg/day increased progression-free survival to 11.4 months in comparison to 5.5 months with placebo in patients with predominantly grade 1-2 panNETs. Overall survival did increase from 29.1 to 38.6 months. In this trial, only one patient with a somatostatinoma was included in the treatment arm (52, 53).

**Chemotherapy**

Chemotherapy is also effective for the treatment of panNEN but no specific data for somatostatinoma are available (44, 54).

**REFERENCES**

1. de Herder WW, Rehfeld JF, Kidd M, Modlin IM. A short history of neuroendocrine tumours and their peptide hormones. Best Pract Res Clin Endocrinol Metab. 2016;30(1):3-17.

2. Schubert ML, Rehfeld JF. Gastric Peptides-Gastrin and Somatostatin. Compr Physiol. 2019;10(1):197-228.

3. Larsson LI, Hirsch MA, Holst JJ, Ingemansson S, Kühl C, Jensen SL, et al. Pancreatic somatostatinoma. Clinical features and physiological implications. Lancet. 1977;1(8013):666-8.

4. Ganda OP, Weir GC, Soeldner JS, Legg MA, Chick WL, Patel YC, et al. "Somatostatinoma": a somatostatin-containing tumor of the endocrine pancreas. N Engl J Med. 1977;296(17):963-7.

5. Krejs GJ, Collins SM, McCarthy D, Unger RH, Gardner JD. Follow-up of a patient with somatostatinoma. N Engl J Med. 1986;315(20):1295.

6. Krejs GJ, Orci L, Conlon JM, Ravazzola M, Davis GR, Raskin P, et al. Somatostatinoma syndrome. Biochemical, morphologic and clinical features. N Engl J Med. 1979;301(6):285-92.

7. Garbrecht N, Anlauf M, Schmitt A, Henopp T, Sipos B, Raffel A, et al. Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity. Endocr Relat Cancer. 2008;15(1):229-41.

8. Mastoraki A, Schizas D, Papoutsi E, Ntella V, Kanavidis P, Sioulas A, et al. Clinicopathological Data and Treatment Modalities for Pancreatic Somatostatinomas. In Vivo. 2020;34(6):3573-82.

9. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 15-1989. A 52-year-old man with neurofibromatosis and jaundice. N Engl J Med. 1989;320(15):996-1004.

10. Thavaraputta S, Graham S, Rivas Mejia AM, Lado-Abeal J. Duodenal somatostatinoma presenting as obstructive jaundice with the coexistence of a gastrointestinal stromal tumour in neurofibromatosis type 1: a case with review of the literature. BMJ Case Rep. 2019;12(1).

11. Crona J, Norlén O, Antonodimitrakis P, Welin S, Stålberg P, Eriksson B. Multiple and Secondary Hormone Secretion in Patients With Metastatic Pancreatic Neuroendocrine Tumours. J Clin Endocrinol Metab. 2016;101(2):445-52.

12. de Mestier L, Hentic O, Cros J, Walter T, Roquin G, Brixi H, et al. Metachronous hormonal syndromes in patients with pancreatic neuroendocrine tumors: a case-series study. Ann Intern Med. 2015;162(10):682-9.

13. Roos BA, Lindall AW, Ells J, Elde R, Lambert PW, Birnbaum RS. Increased plasma and tumor somatostatin-like immunoreactivity in medullary thyroid carcinoma and small cell lung cancer. J Clin Endocrinol Metab. 1981;52(2):187-94.

14. Berelowitz M, Szabo M, Barowsky HW, Arbel ER, Frohman LA. Somatostatin-like immunoactivity and biological activity is present in a human pheochromocytoma. J Clin Endocrinol Metab. 1983;56(1):134-8.

15. Niederle B, Selberherr A, Bartsch D, Brandi ML, Doherty GM, Falconi M, et al. Multiple Endocrine Neoplasia Type 1 (MEN1) and the Pancreas - Diagnosis and Treatment of Functioning and Non-Functioning Pancreatic and Duodenal Neuroendocrine Neoplasia within the MEN1 Syndrome - An International Consensus Statement. Neuroendocrinology. 2020.

16. Lévy-Bohbot N, Merle C, Goudet P, Delemer B, Calender A, Jolly D, et al. Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry. Gastroenterol Clin Biol. 2004;28(11):1075-81.

17. Hammel PR, Vilgrain V, Terris B, Penfornis A, Sauvanet A, Correas JM, et al. Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d'Etude de la Maladie de von Hippel-Lindau. Gastroenterology. 2000;119(4):1087-95.

18. Maki M, Kaneko Y, Ohta Y, Nakamura T, Machinami R, Kurokawa K. Somatostatinoma of the pancreas associated with von Hippel-Lindau disease. Intern Med. 1995;34(7):661-5.

19. Karasawa Y, Sakaguchi M, Minami S, Kitano K, Kawa S, Aoki Y, et al. Duodenal somatostatinoma and erythrocytosis in a patient with von Hippel-Lindau disease type 2A. Intern Med. 2001;40(1):38-43.

20. Deschamps L, Dokmak S, Guedj N, Ruszniewski P, Sauvanet A, Couvelard A. Mixed endocrine somatostatinoma of the ampulla of vater associated with a neurofibromatosis type 1: a case report and review of the literature. Jop. 2010;11(1):64-8.

21. Kumar T, Gupta B, Das P, Jain D, Jain HA, Madhusudhan KS, et al. Combined presence of multiple gastrointestinal stromal tumors along with duodenal submucosal somatostatinoma in a patient with neurofibromatosis type 1. Indian J Pathol Microbiol. 2016;59(3):359-61.

22. Luna IE, Monrad N, Binderup T, Boisen Thoegersen C, Hilsted L, Jensen C, et al. Somatostatin-Immunoreactive Pancreaticoduodenal Neuroendocrine Neoplasms: Twenty-Three Cases Evaluated according to the WHO 2010 Classification. Neuroendocrinology. 2016;103(5):567-77.

23. Martin S, Fica S, Parfeni O, Popa L, Manuc T, Rizea O, et al. Somatostatinoma and Neurofibromatosis Type 1-A Case Report and Review of the Literature. Diagnostics (Basel). 2020;10(9).

24. Sandru F, Carsote M, Valea A, Albu SE, Petca RC, Dumitrascu MC. Somatostatinoma: Beyond neurofibromatosis type 1 (Review). Exp Ther Med. 2020;20(4):3383-8.

25. Därr R, Nambuba J, Del Rivero J, Janssen I, Merino M, Todorovic M, et al. Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome. Endocr Relat Cancer. 2016;23(12):899-908.

26. Dwight T, Kim E, Bastard K, Benn DE, Eisenhofer G, Richter S, et al. Functional significance of germline EPAS1 variants. Endocr Relat Cancer. 2020.

27. Pacak K, Jochmanova I, Prodanov T, Yang C, Merino MJ, Fojo T, et al. New syndrome of paraganglioma and somatostatinoma associated with polycythemia. J Clin Oncol. 2013;31(13):1690-8.

28. Pang Y, Gupta G, Jha A, Yue X, Wang H, Huynh TT, et al. Nonmosaic somatic HIF2A mutations associated with late onset polycythemia-paraganglioma syndrome: Newly recognized subclass of polycythemia-paraganglioma syndrome. Cancer. 2019;125(8):1258-66.

29. Tella SH, Taïeb D, Pacak K. HIF-2alpha: Achilles' heel of pseudohypoxic subtype paraganglioma and other related conditions. Eur J Cancer. 2017;86:1-4.

30. Yang C, Hong CS, Prchal JT, Balint MT, Pacak K, Zhuang Z. Somatic mosaicism of EPAS1 mutations in the syndrome of paraganglioma and somatostatinoma associated with polycythemia. Hum Genome Var. 2015;2:15053.

31. Yang C, Sun MG, Matro J, Huynh TT, Rahimpour S, Prchal JT, et al. Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas. Blood. 2013;121(13):2563-6.

32. Zhuang Z, Yang C, Lorenzo F, Merino M, Fojo T, Kebebew E, et al. Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med. 2012;367(10):922-30.

33. Caplin ME, Ratnayake GM. Diagnostic and therapeutic advances in neuroendocrine tumours. Nat Rev Endocrinol. 2020.

34. Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2016;103(2):153-71.

35. Hofland J, Kaltsas G, de Herder WW. Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms. Endocr Rev. 2020;41(2).

36. Rindi G, Klersy C, Albarello L, Baudin E, Bianchi A, Buchler MW, et al. Competitive Testing of the WHO 2010 versus the WHO 2017 Grading of Pancreatic Neuroendocrine Neoplasms: Data from a Large International Cohort Study. Neuroendocrinology. 2018;107(4):375-86.

37. Perren A, Couvelard A, Scoazec JY, Costa F, Borbath I, Delle Fave G, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology: Diagnosis and Prognostic Stratification. Neuroendocrinology. 2017;105(3):196-200.

38. Partelli S, Bartsch DK, Capdevila J, Chen J, Knigge U, Niederle B, et al. ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours. Neuroendocrinology. 2017;105(3):255-65.

39. Frilling A, Modlin IM, Kidd M, Russell C, Breitenstein S, Salem R, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15(1):e8-21.

40. Frilling A, Al-Nahhas A, Clift AK. Transplantation and Debulking Procedures for Neuroendocrine Tumors. Front Horm Res. 2015;44:164-76.

41. Frilling A, Clift AK. Surgical Approaches to the Management of Neuroendocrine Liver Metastases. Endocrinol Metab Clin North Am. 2018;47(3):627-43.

42. Partelli S, Inama M, Rinke A, Begum N, Valente R, Fendrich V, et al. Long-Term Outcomes of Surgical Management of Pancreatic Neuroendocrine Tumors with Synchronous Liver Metastases. Neuroendocrinology. 2015;102(1-2):68-76.

43. Pavel M, Öberg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844-60.

44. Pavel M, Valle JW, Eriksson B, Rinke A, Caplin M, Chen J, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents. Neuroendocrinology. 2017;105(3):266-80.

45. Halfdanarson TR, Strosberg JR, Tang L, Bellizzi AM, Bergsland EK, OʼDorisio TM, et al. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. Pancreas. 2020;49(7):863-81.

46. Angeletti S, Corleto VD, Schillaci O, Marignani M, Annibale B, Moretti A, et al. Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours. Gut. 1998;42(6):792-4.

47. Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224-33.

48. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376(2):125-35.

49. Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, et al. Long-Term Efficacy, Survival, and Safety of [(177)Lu-DOTA(0),Tyr(3)]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors. Clin Cancer Res. 2017;23(16):4617-24.

50. Zandee WT, Brabander T, Blazevic A, Kam BLR, Teunissen JJM, Feelders RA, et al. Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors. J Clin Endocrinol Metab. 2019;104(4):1336-44.

51. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514-23.

52. Herrera-Martinez AD, Hofland J, Hofland LJ, Brabander T, Eskens F, Galvez Moreno MA, et al. Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives. Drugs. 2019;79(1):21-42.

53. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501-13.

54. Garcia-Carbonero R, Rinke A, Valle JW, Fazio N, Caplin M, Gorbounova V, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms. Systemic Therapy 2: Chemotherapy. Neuroendocrinology. 2017;105(3):281-94.